کد مقاله کد نشریه سال انتشار مقاله انگلیسی نسخه تمام متن
2104161 1546275 2014 6 صفحه PDF دانلود رایگان
عنوان انگلیسی مقاله ISI
Bortezomib for Refractory Autoimmunity in Pediatrics
موضوعات مرتبط
علوم زیستی و بیوفناوری بیوشیمی، ژنتیک و زیست شناسی مولکولی تحقیقات سرطان
پیش نمایش صفحه اول مقاله
Bortezomib for Refractory Autoimmunity in Pediatrics
چکیده انگلیسی

Therapy of refractory autoimmunity remains challenging. In this study, we evaluated the therapeutic effect of bortezomib, a proteasome inhibitor, by targeting plasma cells in 7 patients (median age, 9.9 years). Four doses of bortezomib were administered at a dose of 1.3 mg/m2 intravenously (n = 6) or subcutaneously (n = 1) every 72 hours. Bortezomib was administered at a median of 120 days from laboratory confirmation of autoantibodies. All patients had failed 2 or more standard therapies. Rituximab was administered on the first day if B cells were present, and all patients received plasmapheresis 2 hours before bortezomib administration. Six patients experienced resolution of cytopenias. Two of 6 patients experienced recurrence of cytopenias after initial response. Adverse effects include nausea (n = 1), thrombocytopenia (n = 2), Clostridium difficile colitis (n = 1)), febrile neutropenia (n = 1), and cellulitis at the subcutaneous injection site (n = 1). Our experience suggests that bortezomib may be beneficial in the treatment of refractory autoimmunity in children.

ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: - Volume 20, Issue 10, October 2014, Pages 1654–1659
نویسندگان
, , , , , , , ,